Does Cigna Cover Farxiga (Dapagliflozin)?

Cigna Formulary Placement for Farxiga

Cigna places Farxiga (dapagliflozin 5 mg and 10 mg tablets) on either Tier 3 or Tier 4 of its commercial formulary, depending on the specific plan. Tier 3 is the preferred brand level, and Tier 4 is the non-preferred brand level. This placement determines your copay or coinsurance.

On a Tier 3 plan, a typical copay ranges from $35 to $75 per 30-day fill. Tier 4 placement usually means coinsurance of 25% to 50% of the drug's cost, which can push out-of-pocket spending above $150 per month. Cigna's Open Access Plus and HMO plans frequently differ on tier assignment, so checking your specific plan's formulary document is the first step. Your plan's Summary of Benefits and Coverage (SBC) will list the exact cost-sharing structure.

SGLT2 inhibitors as a class have gained favorable formulary positioning since the FDA expanded dapagliflozin's label beyond type 2 diabetes. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in worsening heart failure or cardiovascular death with dapagliflozin 10 mg versus placebo, which prompted broader payer coverage across multiple indications [1]. Cigna's medical policy documents explicitly reference heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) as covered indications, not only type 2 diabetes.

The formulary can change at the start of each plan year. A drug that sat on Tier 3 in 2025 may shift to Tier 4 in 2026 after contract renegotiation between Cigna and AstraZeneca.

Prior Authorization Requirements

Cigna requires prior authorization (PA) for Farxiga across nearly all commercial plan types. The PA process is rated moderate difficulty, meaning most requests are approved if documentation is complete, but incomplete submissions are routinely rejected on the first pass.

To satisfy Cigna's PA criteria, prescribers generally need to submit three things: a confirmed diagnosis of type 2 diabetes, HFrEF, or CKD; documentation of prior therapy (usually metformin for diabetes indications); and lab values supporting the clinical need. For CKD, Cigna typically looks for an eGFR between 25 and 75 mL/min/1.73 m², aligning with the population studied in the DAPA-CKD trial (N=4,304), which showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death [2].

For heart failure indications, Cigna's coverage policy references an ejection fraction of 40% or less. The prescriber must document that the patient is already on guideline-directed medical therapy (GDMT), including an ACE inhibitor or ARB (or sacubitril/valsartan), a beta-blocker, and a mineralocorticoid receptor antagonist, unless contraindicated. This aligns with the 2022 AHA/ACC/HFSA heart failure guideline, which gives SGLT2 inhibitors a Class I recommendation for HFrEF [3].

PA decisions typically arrive within 72 hours for standard requests and 24 hours for urgent requests. If your prescriber marks the request as urgent and the pharmacy transmits it electronically through CoverMyMeds or SureScripts, turnaround can drop to under 12 hours.

Step Therapy: What Cigna Requires First

Cigna applies step therapy protocols to Farxiga for the type 2 diabetes indication. This means your prescriber must document that you tried and either failed or could not tolerate a first-line agent before Cigna will approve dapagliflozin.

The step therapy requirement is straightforward for most patients. Cigna's standard step edit requires a 90-day trial of metformin (or documented intolerance/contraindication to metformin) before authorizing an SGLT2 inhibitor. Metformin intolerance is common. Gastrointestinal side effects affect roughly 20% to 30% of patients, according to a 2017 meta-analysis published in Diabetes, Obesity and Metabolism [4]. Documenting GI intolerance in the patient's chart is usually sufficient to bypass the metformin step.

Step therapy does not apply the same way to heart failure or CKD indications. For those, Cigna evaluates GDMT compliance rather than diabetes-specific step therapy. A patient with HFrEF who has never taken metformin will not be required to trial it.

If your prescriber receives a step therapy rejection, the fastest path forward is a step therapy exception request, not a standard appeal. Cigna has a distinct exception pathway for step edits, and the prescriber can submit clinical rationale (such as lactic acidosis risk, eGFR <30, or hepatic impairment) to override the metformin requirement.

How Much Farxiga Costs With Cigna

The sticker price matters less than what you actually pay. Farxiga's wholesale acquisition cost (WAC) is approximately $620 per month for a 30-day supply of either 5 mg or 10 mg tablets, according to FDA label and pricing databases [5].

With Cigna Tier 3 coverage, out-of-pocket costs typically fall between $35 and $75 per fill after PA approval. Tier 4 placement raises that range to $100 to $300 depending on your plan's coinsurance percentage. Cigna Medicare Advantage plans may apply different cost-sharing rules, with some placing SGLT2 inhibitors on a specialty tier.

AstraZeneca offers a manufacturer copay savings card that can reduce the copay to as low as $0 per month for commercially insured patients. The card covers up to $250 per 30-day prescription, and patients can use it for up to 24 months. Cigna's commercial plans generally allow copay card stacking, but Cigna Medicare Advantage and Cigna Medicaid plans prohibit manufacturer card use due to federal anti-kickback regulations.

For patients hitting the donut hole on Medicare Part D, dapagliflozin costs can spike. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs (effective 2025) helps, but Cigna Medicare Advantage plans with integrated Part D may structure cost-sharing differently than standalone Part D.

How to Appeal a Cigna Denial for Farxiga

A denial is not the end. Cigna uses a two-level internal appeal process followed by an external independent review organization (IRO) appeal. Understanding each level increases your chances of reversal.

Level 1 internal appeal. You or your prescriber must file this within 60 days of the denial letter. Include the original PA documentation plus any new clinical evidence. If the denial was for step therapy noncompliance, attach chart notes showing metformin intolerance or contraindication. If the denial was for medical necessity, include relevant trial data. The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin reduced hospitalization for heart failure by 27% in patients with type 2 diabetes and multiple cardiovascular risk factors [6]. Citing this trial alongside the patient's specific risk profile strengthens the medical necessity argument.

Level 2 internal appeal. If Level 1 fails, a second internal review is conducted by a different Cigna medical director who was not involved in the first decision. New evidence can be submitted at this stage. Peer-to-peer review (a phone call between your prescriber and Cigna's reviewing physician) is available at both levels and often resolves disputes faster than written submissions alone.

External IRO appeal. After exhausting both internal levels, you can request an external review by an independent organization. The external reviewer is a board-certified physician who evaluates the case without any financial relationship to Cigna. External reviews overturn insurer denials in roughly 40% to 60% of cases for specialty medications, according to data from the National Association of Insurance Commissioners.

Keep copies of every submission. Cigna is required to issue a written decision within 30 calendar days for standard appeals and 72 hours for expedited appeals involving urgent clinical need.

Farxiga Coverage for Specific Conditions

Cigna's coverage criteria differ depending on the approved indication. Here is how each breaks down.

Type 2 diabetes. PA required. Step therapy with metformin required. Cigna approves dapagliflozin as add-on therapy when A1C remains above target (typically ≥7.0%) despite metformin at maximally tolerated doses. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred second-line agents in patients with established cardiovascular disease, heart failure, or CKD, regardless of A1C [7].

Heart failure (HFrEF). PA required. No diabetes-specific step therapy. Cigna covers dapagliflozin 10 mg for patients with NYHA Class II, IV heart failure and an ejection fraction ≤40%, provided GDMT is documented. Coverage extends to patients without diabetes, based on DAPA-HF data showing benefit regardless of diabetes status [1].

Chronic kidney disease. PA required. No diabetes-specific step therapy. Cigna covers dapagliflozin 10 mg for CKD patients with eGFR 25 to 75 mL/min/1.73 m² and urine albumin-to-creatinine ratio ≥200 mg/g, consistent with the DAPA-CKD inclusion criteria [2]. Some Cigna plans have expanded coverage to broader CKD populations following the 2024 KDIGO CKD guideline update, which recommended SGLT2 inhibitors for all CKD patients with eGFR ≥20 mL/min/1.73 m² [8].

Weight loss (off-label). Not covered. Cigna does not authorize Farxiga for weight loss as a standalone indication. While SGLT2 inhibitors produce modest weight reduction (typically 2 to 3 kg), this effect is considered secondary and does not meet Cigna's medical necessity criteria for obesity treatment.

Tips for Getting Farxiga Approved Through Cigna

A clean submission prevents delays. These steps reduce the chance of denial.

Start by verifying your plan's formulary before the prescriber submits. Call the number on the back of your Cigna card and ask specifically which tier Farxiga occupies and whether step therapy applies. Get the reference number for the call.

Ask your prescriber to submit PA electronically through CoverMyMeds. Electronic submissions are processed faster than fax-based requests and create a traceable record. Include the ICD-10 code that matches the FDA-approved indication (E11.65 for type 2 diabetes with hyperglycemia, I50.2x for systolic heart failure, N18.3/N18.4 for CKD stage 3 to 4).

If step therapy is required and you have already tried metformin with another provider or health plan, obtain those records. Cigna accepts documentation of prior metformin use from other insurers as evidence of step completion.

For heart failure or CKD indications, include the most recent echocardiogram report (for HF) or comprehensive metabolic panel with eGFR and UACR (for CKD) with the PA submission. Missing labs are the most common reason for PA processing delays.

If your out-of-pocket cost remains high after PA approval, enroll in the AstraZeneca savings program at the point of sale. The pharmacy can process the savings card as a secondary payer at the time of fill, reducing your copay immediately rather than requiring a mail-in rebate.

Patients prescribed dapagliflozin 10 mg should have serum creatinine, potassium, and blood pressure monitored within 1 to 2 weeks of starting therapy, per the FDA prescribing information [5]. Cigna does not mandate specific monitoring intervals, but documentation of appropriate follow-up strengthens future reauthorization requests.